Magnetically assisted intraperitoneal drug delivery for cancer chemotherapy

Drug Deliv. 2018 Nov;25(1):846-861. doi: 10.1080/10717544.2018.1455764.

Abstract

Intraperitoneal (IP) chemotherapy has revived hopes during the past few years for the management of peritoneal disseminations of digestive and gynecological cancers. Nevertheless, a poor drug penetration is one key drawback of IP chemotherapy since peritoneal neoplasms are notoriously resistant to drug penetration. Recent preclinical studies have focused on targeting the aberrant tumor microenvironment to improve intratumoral drug transport. However, tumor stroma targeting therapies have limited therapeutic windows and show variable outcomes across different cohort of patients. Therefore, the development of new strategies for improving the efficacy of IP chemotherapy is a certain need. In this work, we propose a new magnetically assisted strategy to elevate drug penetration into peritoneal tumor nodules and improve IP chemotherapy. A computational model was developed to assess the feasibility and predictability of the proposed active drug delivery method. The key tumor pathophysiology, including a spatially heterogeneous construct of leaky vasculature, nonfunctional lymphatics, and dense extracellular matrix (ECM), was reconstructed in silico. The transport of intraperitoneally injected magnetic nanoparticles (MNPs) inside tumors was simulated and compared with the transport of free cytotoxic agents. Our results on magnetically assisted delivery showed an order of magnitude increase in the final intratumoral concentration of drug-coated MNPs with respect to free cytotoxic agents. The intermediate MNPs with the radius range of 200-300 nm yield optimal magnetic drug targeting (MDT) performance in 5-10 mm tumors while the MDT performance remains essentially the same over a large particle radius range of 100-500 nm for a 1 mm radius small tumor. The success of MDT in larger tumors (5-10 mm in radius) was found to be markedly dependent on the choice of magnet strength and tumor-magnet distance while these two parameters were less of a concern in small tumors. We also validated in silico results against experimental results related to tumor interstitial hypertension, conventional IP chemoperfusion, and magnetically actuated movement of MNPs in excised tissue.

Keywords: Intraperitoneal drug delivery; computational and mathematical tumor modeling; desmoplasia; drug penetration depth; interstitial hypertension; magnetic drug targeting; tumor microenvironment.

Publication types

  • Comparative Study
  • Validation Study

MeSH terms

  • Absorption, Physiological*
  • Algorithms
  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use
  • Computational Biology
  • Computer Simulation
  • Drug Delivery Systems*
  • Expert Systems
  • Extracellular Fluid / metabolism
  • Feasibility Studies
  • Humans
  • Injections, Intralesional
  • Injections, Intraperitoneal
  • Magnetic Phenomena*
  • Magnetite Nanoparticles / chemistry*
  • Models, Biological*
  • Particle Size
  • Peritoneal Neoplasms / blood supply
  • Peritoneal Neoplasms / drug therapy*
  • Peritoneal Neoplasms / pathology
  • Peritoneal Neoplasms / secondary
  • Tissue Distribution
  • Tumor Burden

Substances

  • Antineoplastic Agents
  • Magnetite Nanoparticles

Grants and funding

This work was supported by the Natural Sciences and Engineering Research of Canada (NSERC) and Alberta Innovates BioSolutions.